Grail Inc (GRAL)
NASDAQ:GRAL
Want to see GRAL full AI Analyst Report?
Earnings Data
Report Date
Aug 18, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-2.75Last Year’s EPS
-3.18Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical and regulatory progress: test volumes grew 50% YoY, screening revenue rose 37% YoY, adjusted gross profit improved 38% YoY, PMA was accepted, and large trial datasets and upcoming ASCO readouts support the evidence base. At the same time, the NHS-Galleri primary combined endpoint was not met, ASP pressure and continued operating losses persist, media scrutiny and competitive activity create near-term headwinds, and regulatory/timing uncertainties (including possible FDA AdCom and CMS coverage) remain. Overall, positives around volume growth, margins improvement, cash runway, partnerships and regulatory progress outweigh the challenges, but the company still faces execution and perception risks that will need to be addressed in coming quarters.Company Guidance
Strong Volume and Screening Revenue Growth
Galleri tests sold: >56,000 in Q1 2026, a 50% year-over-year increase. Galleri screening revenue: $39.8M, up 37% year-over-year. Total revenue: $40.8M, up 28% year-over-year (includes $1.0M development services).
Improved Unit Economics and Gross Profit
Non-GAAP adjusted gross profit of $19.7M in Q1 2026, an increase of $5.4M or 38% year-over-year. Margin improvement driven by fixed cost leverage from higher volumes and reduced sample reprocessing costs.
Progress on Adjusted EBITDA and Cash Position
Adjusted EBITDA was negative $79.9M, an improvement of $18.8M or 19% year-over-year. Cash balance of $823.1M at quarter end, providing multi-year runway to pursue milestones and commercialization.
Regulatory Milestone: PMA Submission Accepted
FDA PMA submission for Galleri was accepted for review (PMA includes ~25,000 PATHFINDER 2 participants with 1-year follow-up and the prevalence round of NHS-Galleri, plus a bridging analysis). Company notes ongoing iterative review and constructive interactions with FDA.
Large Evidence Base and Upcoming Data Readouts
More than 174,000 individuals included in studies supporting the PMA; PATHFINDER 2 (35,000 participants) and NHS-Galleri (140,000 participants) full results to be presented at ASCO. Commercial and study testing yields consistent results across hundreds of thousands of tests.
Clinical Utility Findings from NHS-Galleri
NHS-Galleri topline: increase in detection of Stage I/II deadly cancers and a fourfold higher cancer detection rate compared to standard of care screening alone; meaningful reductions observed in Stage IV diagnoses and emergency presentations of cancer.
Commercial Partnerships and System Integrations
Expanded partnerships with major health systems (Dana-Farber, Cleveland Clinic, Duke, OHSU, Rush, Intermountain), digital-health partners (Function Health, Hims & Hers, WHOOP, Everlywell) and employers. Integrations with Quest and Athena have enabled ~2,000 providers to order via those platforms, yielding >30,000 tests through those integrations; Epic Aura integration announced (targeting ~450 Epic health systems eligible) to streamline ordering and results in EHRs.
Sales Force Expansion
Planned expansion of field sales and medical teams to increase territories from ~90 to 120; majority of new sales personnel expected to be onboarded and trained by midyear to drive further commercial momentum.
GRAL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GRAL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $54.40 | $62.75 | +15.35% |
Feb 19, 2026 | $101.53 | $50.21 | -50.55% |
Nov 12, 2025 | $84.77 | $83.20 | -1.85% |
Aug 12, 2025 | $33.60 | $33.98 | +1.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Grail Inc (GRAL) report earnings?
Grail Inc (GRAL) is schdueled to report earning on Aug 18, 2026, After Close (Confirmed).
What is Grail Inc (GRAL) earnings time?
Grail Inc (GRAL) earnings time is at Aug 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GRAL EPS forecast?
GRAL EPS forecast for the fiscal quarter 2026 (Q2) is -2.75.